1. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol. 2017;101(6):130–195. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583689/pdf/bjophthalmol-2016-EGSguideline.003.pdf2. Konstas AG, Quaranta L, Bozkurt B, et al. 24-h Efficacy of Glaucoma Treatment Options [published correction appears in Adv Ther. 2016 Apr;33(4):518]. Adv Ther. 2016;33(4):481–517. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846688/pdf/12325_2016_Article_302.pdf3. Sihota R, Angmo D, Ramaswamy D, Dada T. Simplifying "target" intraocular pressure for different stages of primary open-angle glaucoma and primary angle-closure glaucoma. Indian J Ophthalmol. 2018;66(4):495–505. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892050/?report=reader 4. Wesselink C, Stoutenbeek R, Jansonius NM. Incorporating life expectancy in glaucoma care. Eye (Lond). 2011;25(12):1575–1580. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234462/pdf/eye2011213a.pdf 5. Cohen LP, Pasquale LR. Clinical characteristics and current treatment of glaucoma. Cold Spring Harb Perspect Med. 2014;4(6):a017236. Published 2014 Jun 2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4031956/pdf/cshperspectmed-RET-a017236.pdf 6. Parikh RS, Parikh SR, Navin S, Arun E, Thomas R. Practical approach to medical management of glaucoma. Indian J Ophthalmol. 2008;56(3):223–230. "The philosophy of glaucoma management is to preserve the visual function and quality of life (QOL) of the individual. Essentially, (functional) vision should outlast the patient. Our aim is not to treat just the intraocular pressure (IOP), optic disc or visual field, but to treat the patient as a whole so as to provide maximum benefit with minimal side effects." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636120/ 7. Jay JL, Murdoch JR. The rate of visual field loss in untreated primary open angle glaucoma. Br J Ophthalmol. 1993;77(3):176–178. " For pressures of 21 to 25 mm Hg, untreated disease is likely to progress from early field changes to end stage in an average of 14.4 years. The same interval for pressures of 25 to 30 mm Hg was 6.5 years and for pressures over 30 mm Hg, 2.9 years. For untreated disease at pressures over 25 mm Hg the interval is estimated at 3.6 years and this is much shorter than the estimated period of 10 years under imperfect treatment and 38 years under optimum treatment identified in a prospective clinical trial..." https://www.ncbi.nlm.nih.gov/pmc/articles/PMC504466/pdf/brjopthal00039-0044.pdf 8. Heijl A. The times they are a-changin': time to change glaucoma management. Acta Ophthalmol. 2013;91(1):92–99. https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1755-3768.2011.02328.x 9. Susanna R Jr, De Moraes CG, Cioffi GA, Ritch R. Why Do People (Still) Go Blind from Glaucoma?. Transl Vis Sci Technol. 2015;4(2):1. Published 2015 Mar 9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354096/pdf/i2164-2591-4-2-1.pdf 10. Kastner A, King AJ. Advanced glaucoma at diagnosis: current perspectives. Eye (Lond). 2020;34(1):116-128. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002722/ 11. Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in Glaucoma: From the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021 Jul;83:100916. https://www.sciencedirect.com/science/article/pii/S1350946220300884?via%3Dihub